Comparative Study between Platelet-Rich Plasma, Corticosteroids and Perineural Dextrose local Injections for Treatment of Carpal Tunnel Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202310697176998

Enrollment

Registered

2023-10-25

Start date

2017-11-08

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Diseases

Interventions

Local corticosteroids

Perineural Dextrose injection

Platelet rich plasma injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients included in the study were diagnosed with mild and moderate idiopathic carpal tunnel syndrome With clinical symptoms for at least 3 months, and According to the electrophysiological studies classification of carpal tunnel syndrome into mild, moderate as follows: Mild CTS: Prolonged distal motor latency( DML) but less than 150% of the highest normal value (5.4 ms); Slowed sensory nerve conduction velocity (SNCV) but greater than 75% of the lowest normal value (30.1 m/s), Reduced compound muscle action potential (CMAP) or sensory nerve action potential (SNAP) amplitude but greater than 75% of the lowest normal value (CMAP: 3.9 mV, SNAP: 6.1 mV), Mildly increased polyphasic waves or duration of motor units action potential (MUAPs) in electromyography (EMG) tests. Moderate CTS: Prolonged distal latencies at the range of 150% to 200% of the highest normal value (5.4–7.2 ms), Slowed SNCV at the range of 50% to 75% of the lowest normal value (20–30 m/s), Reduced CMAP or SNAP amplitude at the range of 50% to 75% of the lowest normal value (CMAP: 2.5–3.8 mV, SNAP: 4.0–6.0 mV) Markedly increased polyphasic waves or duration of (MUAPs) in EMG tests.

Exclusion criteria

Exclusion criteria: Patients with a history and symptoms consistent with: Severe carpal tunnel syndrome (wasting of thenar muscles) Cervical radiculopathy Thoracic outlet syndrome Brachial plexopathies Secondary CTS e.g.: Diabetes mellitus Rheumatoid arthritis Myxedema Acromegaly Pregnancy Oral contraceptive pills intake Fracture or dislocation of carpal bone Patient on chemotherapy or radiotherapy or cardiac drugs Peripheral median nerve trauma Patients with carpal tunnel syndrome who underwent surgical operation Patients with coagulation disorders, Seizure disorders and severe psychiatric illness Renal and liver impairment Skin diseases at site of injection.

Design outcomes

Primary

Measure	Time frame
The result of this study may determine which treatment may be more beneficial for treatment of carpal tunnel syndrome	—

Secondary

Measure	Time frame
All of the three studied groups (corticosteroids, perineural dextrose and platelet rich plasma) have shown a great result regarding improving in clinical examination, clinical assessment scales, nerve conduction studies and improving in neuromuscular ultrasound results of carpal tunnel syndrome with favorable results of corticosteroids group over perineural dextrose group and platelet rich plasma group.	—

Measure

Time frame

All of the three studied groups (corticosteroids, perineural dextrose and platelet rich plasma) have shown a great result regarding improving in clinical examination, clinical assessment scales, nerve conduction studies and improving in neuromuscular ultrasound results of carpal tunnel syndrome with favorable results of corticosteroids group over perineural dextrose group and platelet rich plasma group.

—

Countries

Egypt

Contacts

Public ContactSarah Sarah Magdy Abbas Mohamed

Assistant lecturer of Rheumatology Rehabilitation and Physical Medicine

dr.saramagdyabbas@gmail.com01001630597

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026